Study identifies potential therapeutic target for treatment of Huntington’s disease

Huntington’s disease is caused by a mutation in the Huntingtin gene (HTT), which appears in adults and features motor, cognitive and psychiatric alterations. The origin of this disease has been associated with the anomalous functioning of the mutated protein: mHTT, but recent data showed the involvement of other molecular mechanisms.

A new study conducted by the University of Barcelona has identified a type of ribonucleic acid (RNA) as a potential therapeutic target for the treatment of the disease. These are the small RNA, or sRNAs, molecules that do not code proteins but have important functions in the regulation of gene expression. According to the study, sRNAs would take part in the development of the disease, results that shed light on the design of new specific drugs to block the activity of these intermediary molecules that help researchers to understand the information in the genes.

The study, published in the journal Acta Neuropathologica, counts on the participation of two teams from the Institute of Neurosciences of the UB, led by the lecturers of the Faculty of Medicine and Health Sciences Eulàlia Martí, also researcher at the Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP); and Esther Pérez-Navarro, also researcher at the Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED) and the August Pi i Sunyer Biomedical Research Institute (IDIBELL), the Center for Genomic Regulation (CRG) and the University Medical Center Göttingen (Germany)…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.